These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 30312680)
1. Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. Ramalingam S; Dinan MA; Crawford J J Thorac Oncol; 2018 Dec; 13(12):1842-1850. PubMed ID: 30312680 [TBL] [Abstract][Full Text] [Related]
2. Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. Ramalingam S; Dinan MA; Crawford J Clin Lung Cancer; 2021 Jul; 22(4):e646-e653. PubMed ID: 33582071 [TBL] [Abstract][Full Text] [Related]
3. The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012. Andreano A; Peake MD; Janes SM; Valsecchi MG; Pritchard-Jones K; Hoag JR; Gross CP J Thorac Oncol; 2018 Jul; 13(7):904-914. PubMed ID: 29727739 [TBL] [Abstract][Full Text] [Related]
4. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412 [TBL] [Abstract][Full Text] [Related]
5. Lung cancer in women, a different disease: survival differences by sex in Turkey. Ulas A; Tokluoglu S; Kos M; Silay K; Akinci S; Oksuzoglu B; Alkis N Asian Pac J Cancer Prev; 2015; 16(2):815-22. PubMed ID: 25684531 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis. Malhotra J; Mhango G; Gomez JE; Smith C; Galsky MD; Strauss GM; Wisnivesky JP Ann Oncol; 2015 Apr; 26(4):768-773. PubMed ID: 25600562 [TBL] [Abstract][Full Text] [Related]
7. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study. Bergqvist M; Christensen HN; Wiklund F; Bergström S Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754 [TBL] [Abstract][Full Text] [Related]
8. Metformin use and lung cancer survival: a population-based study in Norway. Brancher S; Støer NC; Weiderpass E; Damhuis RAM; Johannesen TB; Botteri E; Strand TE Br J Cancer; 2021 Mar; 124(5):1018-1025. PubMed ID: 33262518 [TBL] [Abstract][Full Text] [Related]
9. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer. Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370 [TBL] [Abstract][Full Text] [Related]
10. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer. Lichtenstein MRL; Nipp RD; Muzikansky A; Goodwin K; Anderson D; Newcomb RA; Gainor JF J Thorac Oncol; 2019 Mar; 14(3):547-552. PubMed ID: 30476576 [TBL] [Abstract][Full Text] [Related]
11. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy. Wu XY; Huang XE Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501 [TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer. Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356 [TBL] [Abstract][Full Text] [Related]
14. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848 [TBL] [Abstract][Full Text] [Related]
15. Survival disparities following surgery among patients with different histological types of non-small cell lung cancer. Grosu HB; Manzanera A; Shivakumar S; Sun S; Noguras Gonzalez G; Ost DE Lung Cancer; 2020 Feb; 140():55-58. PubMed ID: 31865279 [TBL] [Abstract][Full Text] [Related]
16. Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities. Begnaud A; Yang P; Robichaux C; Rubin N; Kratzke R; Melzer A; Aliferis C; Jacobson P Clin Lung Cancer; 2020 May; 21(3):e164-e168. PubMed ID: 31759888 [TBL] [Abstract][Full Text] [Related]
17. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer. Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432 [TBL] [Abstract][Full Text] [Related]
18. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]